All In Biotech

Drug Trial Radar · NCT05934513

A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

A Phase Ib/II, Multicentre, Open-label Study to Assess the Efficacy, Safety/ Tolerability and Pharmacokinetic of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Last checked: Nov 19, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

95

Planned (sponsor's estimate)

Start

Sep 6, 2023

Primary completion

Dec 30, 2025

Study completion Jun 30, 2026

Sponsor

Sponsor type
Industry
First posted
Jul 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the efficacy, safety/ tolerability and pharmacokinetic of GFH009 monotherapy in patients with relapsed or refractory peripheral T-cell lymphoma

Conditions

  • Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Interventions

  • GFH009Drug

    patients are planned to be administrated with GFH009 every week in a 21 days cycle, intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib: adverse eventsTime frame: From Screening (Day -28 to Day-1) until disease progression or survival until death (approximately 6 months)
  2. Phase II: Objective Response RateTime frame: From Screening (Day -28 to Day-1) until disease progression or survival until death (approximately 6 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guanzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.